Trial Profile
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2011 Planned End Date changed from 1 Oct 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 28 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.